Home The impact of the COVID-19 pandemic on DKA severity in Black and White pediatric patients
Article Publicly Available

The impact of the COVID-19 pandemic on DKA severity in Black and White pediatric patients

  • Shrina Patel EMAIL logo , Elyzabeth Amador , Jonathan M. Fischell , Erin Bewley , Kaitlin Jeffries , Paula G. Newton and Stefanie Zaner Fischell
Published/Copyright: February 6, 2025

Abstract

Objectives

Diabetic ketoacidosis (DKA) is a complication of uncontrolled diabetes mellitus, with a known increase in severity and incidence during the COVID-19 pandemic. Our institution also observed a rise in pediatric DKA cases in our largely underserved patient population. We hypothesized that the impact would be more pronounced in Black patients due to prepandemic healthcare inequities.

Methods

To investigate this, we confirmed the increased number of severe DKA cases in our pediatric patients during the pandemic and then stratified data to compare laboratory values between Black and White patients. We analyzed patients with a DKA diagnosis admitted to our institution’s pediatric intensive care unit (PICU) prior to the pandemic (March 2016 to December 2017) and during its peak (March 2020 to December 2021).

Results and Conclusions

Our data demonstrated more cases of severe DKA overall during 2020–2021 and when compared to prepandemic years, a statistically significant increase in severity for Black, but not White patients.

Introduction

Diabetic ketoacidosis (DKA) is a severe complication of uncontrolled type 1 and type 2 diabetes mellitus, caused by either absolute or relative insulin deficiency [1]. It can be prompted by various events such as insufficient insulin due to improper insulin dosing/malfunctioning insulin pumps, illness, noncompliance, and limited access to medication, all of which may be exacerbated by health inequity [2]. While many patients recover from DKA with prompt treatment, typically intensive care unit (ICU) admission is required and occasionally patients suffer severe and potentially permanent morbidity such as neurological or respiratory compromise, and even death [2], 3].

It has been documented that in both adult and pediatric patients, the incidence of DKA increased during the COVID-19 pandemic and that children admitted with DKA during the pandemic were likely to have more severe DKA and higher hemoglobin (Hb) A1c [4], 5]. Recent literature has also reported more cases of DKA in non-Hispanic Black vs. non-Hispanic White patients, but these focused on populations with concomitant COVID-19 infection or newly diagnosed type 1 diabetes mellitus [6], 7]. To our knowledge, no study to date has merged these topics in a population where the scope was not limited to COVID-19 infection or first presentation of DKA. We aim to review the pediatric DKA cases at our institution during the peak of the COVID-19 pandemic and identify the impact, if any, that race had on the severity of them.

Methods

A chart review was performed on patients admitted to the University of Maryland PICU for DKA during two different time periods: before the pandemic (March 2016–December 2017) and during the peak of the pandemic (March 2020–December 2021). The study population included all patients admitted and found to have DKA, including those for the first time and those who are not followed by the institution for their outpatient care. There were 214 cases total. These groups were subdivided by self-reported race; however, due to the smaller number of patients identifying as groups other than Black or White, only these two categories were included in further analysis. The final number of included cases was 199. Table 1 provides a detailed breakdown demographic data for patients included in this study. Serum pH on admission were each used independently to stratify DKA severity into “mild”, “moderate”, and “severe” groups. Mild DKA was defined as a pH of 7.25–7.30; moderate DKA was defined as a pH of 7.00–7.24; and severe DKA was defined as a pH<7.00. Frequencies in each group were compared using chi-squared analysis. The mean HbA1c and blood glucose on admission were compared between groups using 2-tailed, unpaired t-tests. Statistical significance was assigned at p<0.05.

Table 1:

Summary of data, demographics and variables of interest.


Demographics

Variables of interest

Total, n

214

Blood pH

Mild, n (%)

Moderate, n (%)

Severe, n (%)

Total, n (%)c
Ethnicity n (%) Overall 43 (21.9) 76 (38.8) 77 (39.3) 196
White or black (included) 199 (93.0) White 9 (13.4) 35 (52.2) 23 (34.3) 67
White 68 (31.8) Black 34 (26.4) 41 (31.8) 54 (41.9) 129
Black 131 (61.2) Pre-Covid 30 (27.0) 42 (37.8) 39 (35.1) 111
Other (excluded) 15 (7.0) Post-Covid 13 (17.3) 24 (32) 38 (50.7) 75
Hispanic 7 (3.3) White/pre-Covid 4 (11.1) 19 (52.8) 13 (36.1) 36
Multiracial/other 6 (2.8) White/during Covid 5 (16.1) 16 (51.6) 10 (32.3) 31
Not reported 2 (0.9) Black/pre-Covid 26 (30.6) 33 (38.8) 26 (30.6) 85
Asian/Pacific Islander 0 (0) Black/during Covid 8 (18.2) 8 (18.2) 28 (63.6) 44
Native American 0 (0)




COVID-19 n (%) Blood glucose
Mean, mg/dL
STD, mg/dL
Total, n c

Pre-Covid 123 (61.8) Overall 566.6 248.7 199
During Covid 76 (38.2) White 511.0 206.2 68
Age n (%) Black 597.6 265.3 131
Age≤12 90 (45.2) Pre-Covid 565.9 249.7 123
Age>12 109 (54.8) During Covid 567.5 248.9 76
Gender n (%) White/pre-Covid 493.3 227.7 36
Male 107 (53.8) White/during Covid 530.4 181.6 32
Female 92 (46.2) Black/pre-Covid 599.3 253.7 87
Diabetes type n (%) Black/during Covid 594.5 287.3 44
Type 1 190 (95.5)




Type 2 6 (3.0) HbA1c
Mean, %
STD, %
Total, n c

Type 1.5, LADA 1 (0.5) Overall 12.3 2.2 181
Not reported 2 (1.0) White 12.0 2.1 67
New diagnosis n (%) Black 12.4 2.3 114
No known hx of DM 60 (30.2) Pre-Covid 12.0 2.0 110
Known hx of DM 136 (68.3) Post-Covid 12.6 2.5 73
Not reported 3 (1.5) White/pre-Covid 12.0 2.1 35
Mean (STD) White/during Covid 12.0 2.1 32
Age, years 12.7 (4.4) Black/pre-Covid 12.1 2.0 75
Years since DM dx (known hx only) 5.7 (3.8) Black/during Covid 13.0 2.8 41
Length of stay, days 3.3 (2.3)
  1. aFor results of “>x”, x was taken as the value. bNormal pH or bicarb included in mild category. cThe number in some cases are lower than total number only if data not reported. dx, diagnosis; hx, history.

Results

For our analysis, we first investigated if patients were presenting with more severe DKA, based on blood pH on admission, before vs. after the onset of the COVID-19 pandemic, in Black compared to White patients (Figure 1A). We found a significant shift to more severe categories of DKA based on blood pH (i.e., mild to moderate or severe and moderate to severe) in Black patients, during COVID compared to White patients, during COVID (p=0.007**) and compared to Black patients before the onset of the pandemic (pre-COVID) (p=0.0014**). There was no difference in DKA severity in Black patients compared to White patients, pre-COVID (p=0.0723, NS); nor was there a significant change in White patients pre- vs. during COVID (p=0.8234, NS).

Figure 1: 
Differential impact of the COVID-19 pandemic on DKA severity and diabetes care in White vs. Black patients. (A) Impact on DKA severity based on blood pH. Significant rightward shift in DKA severity based on blood pH in Black patients compared to White patients during COVID (NWhite/post 31, NBlack/during 44; chi-square 9.930; p=0.007) and in Black patients during COVID compared to pre-COVID (NBlack/pre 85, NBlack/during 44; chi-square 13.14; p=0.0014). (B) No effect of COVID on admission blood glucose in Black or White patients, although, overall Black patients had significantly greater mean blood glucose on admission (NWhite 68, NBlack 131; t=2.348; p=0.0199). (C) No effect of COVID-19 on mean A1c in White patients but statistically significant increase in mean A1c Black patients during COVID (NBlack/pre 75, NBlack/post 41; t=2.004; p=0.0475).
Figure 1:

Differential impact of the COVID-19 pandemic on DKA severity and diabetes care in White vs. Black patients. (A) Impact on DKA severity based on blood pH. Significant rightward shift in DKA severity based on blood pH in Black patients compared to White patients during COVID (NWhite/post 31, NBlack/during 44; chi-square 9.930; p=0.007) and in Black patients during COVID compared to pre-COVID (NBlack/pre 85, NBlack/during 44; chi-square 13.14; p=0.0014). (B) No effect of COVID on admission blood glucose in Black or White patients, although, overall Black patients had significantly greater mean blood glucose on admission (NWhite 68, NBlack 131; t=2.348; p=0.0199). (C) No effect of COVID-19 on mean A1c in White patients but statistically significant increase in mean A1c Black patients during COVID (NBlack/pre 75, NBlack/post 41; t=2.004; p=0.0475).

We next analyzed blood glucose on admission in Black compared to White patients pre and during COVID and found no difference in either group (Black: p=0.9223, NS; White: 0.464, NS) (Figure 1B). However, we did identify that admission blood glucose was higher in Black patients compared to White patients overall irrespective of COVID-19 (p=0.019*).

Finally, we evaluated HbA1c in our sample population, as a marker of chronic diabetes control (Figure 1C). We found a significant increase in HbA1c in Black patients during COVID compared to pre-COVID (p=0.0475*), but not in White patients (p>0.9999, NS). See Table 1 for all specific values related to our data analysis.

Conclusions

Prior literature has identified an increase in DKA incidence and severity during the COVID-19 pandemic [4], [5], [6, 8]​. Our data revealed fewer cases of DKA during the pandemic period, but notably our institution had fewer inpatient admissions in general during this time. This could be due to patient hesitance in those with mild DKA coming to the emergency department or higher thresholds for admission to conserve beds during the pandemic. Using serum pH on admission to classify DKA severity in our pediatric population, we found increased DKA severity during the pandemic compared to prepandemic years in Black, but not White patients.

Separately, Black patients had a significantly higher HbA1c on presentation during the pandemic compared to prepandemic. It is important to note that at baseline, there may be racial differences in red blood cell glycation accounting for elevated HbA1c by approximately 0.4 % in Black vs. White people, even when blood glucose levels are comparable [9]. However, our data revealed that mean prepandemic HbA1c in both groups were quite similar but that the increase in Black patients’ mean HbA1c was 0.9 %, whereas there was no change in that of White patients. The difference seen in these data goes beyond what racial differences can account for. While our analysis did not specifically address the reason behind this finding, one conjecture is that there may be pandemic-exacerbated health disparities that disproportionately affect the Black population [10]​.

The inconsistent utilization of COVID-19 testing early in the pandemic prevented us from being able to reliably report the number of DKA patients who were also COVID-19 positive, which is a limitation of the data. However, the conclusions drawn here will focus on environmental burdens amplified during the pandemic. There are many studies discussing the social determinants of health, which produce the health care disparities that negatively impact achieving optimal glycemic control in Black children [11], 12]​. Transportation barriers to routine health visits, food deserts preventing proper nutrition, limited financial resources, microaggressions in physician–patient relationships, and inadequate health literacy all contribute to health inequities. During the pandemic, society as a whole suffered: diets worsened, mental health deteriorated, and healthcare access narrowed [13]. These changes were more prominent in minorities who often did not have the financial, educational, or social means to maintain optimal health during adverse situations. As diabetes is a complicated chronic medical condition, prepandemic challenges exacerbated during the pandemic likely played a multifactorial role in the increase in the frequency and severity of DKA admissions and increasing HbA1c measurements.

As previously mentioned, the greatest concern is that the pandemic exacerbated preexisting obstacles to care for the Black population. While ongoing research is conducted, this study should prompt healthcare providers to identify and address barriers to care. Actions could include dedicating more time to educate at-risk patients and their caregivers on the signs and symptoms of DKA and how to promptly implement sick day management; providing regular medication check-ins via virtual platforms or telephone; identifying transportation difficulties that impact access to care; addressing food insecurity; and continuing to scrutinize implicit biases when caring for underrepresented minorities.


Corresponding author: Shrina Patel, MD, Department of Pediatrics, University of Maryland Medical Center, 22S. Greene Street, N5W70, Baltimore, MD 21201, USA, E-mail:
Shrina Patel is first author. Elyzabeth Amador, Jonathan M. Fischell, Erin Bewley, Kaitlin Jeffries, and Paula G. Newton contributed equally to this work. Stefanie Zaner Fischell is senior author.

Acknowledgments

The authors thank Adrian J. Holloway, MD for his contribution of Pediatric Intensive Care Unit data for analysis.

  1. Research ethics: The local Institutional Review Board deemed the study exempt from review.

  2. Informed consent: Not applicable.

  3. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: The authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: Not applicable.

References

1. Jensen, ET, Stafford, JM, Saydah, S, D’Agostino, RB, Dolan, LM, Lawrence, JM, et al.. Increase in prevalence of diabetic ketoacidosis at diagnosis among youth with type 1 diabetes: the search for diabetes in youth study. Diabetes Care 2021;44:1573–8. https://doi.org/10.2337/dc20-0389.Search in Google Scholar PubMed PubMed Central

2. EL-Mohandes, N, Huecker, M. Pediatric diabetic ketoacidosis [internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2020. Available from https://www.ncbi.nlm.nih.gov/books/NBK470282/.Search in Google Scholar

3. Moraes, AG de, Surani, S. Effects of diabetic ketoacidosis in the respiratory system. World J Diabetes 2019;10:16–22. https://doi.org/10.4239/wjd.v10.i1.16.Search in Google Scholar PubMed PubMed Central

4. Birkebaek, NH, Kamrath, C, Grimsmann, JM, Aakesson, K, Cherubini, V, Dovc, K, et al.. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. Lancet Diabetes Endocrinol 2022;10. https://doi.org/10.1016/s2213-8587(22)00246-7.Search in Google Scholar PubMed PubMed Central

5. Cymbaluk, A, Huang, X, Minard, C, DeSalvo, D, Redondo, MJ. Diabetic ketoacidosis in youth with diabetes mellitus during the COVID-19 pandemic. J Pediatr Endocrinol Metab 2024;37:759–63. https://doi.org/10.1515/jpem-2024-0107.Search in Google Scholar PubMed

6. Rahmati, M, Keshvari, M, Mirnasuri, S, Yon, DK, Lee, SW, Il Shin, J, et al.. The global impact of COVID‐19 pandemic on the incidence of pediatric new‐onset type 1 diabetes and ketoacidosis: a systematic review and meta‐analysis. J Med Virol 2022;94. https://doi.org/10.1002/jmv.27996.Search in Google Scholar PubMed PubMed Central

7. Osagie, E, Agarwal, S, Noor, N, Albanese-O’Neill, A, Wong, JC, Tossaporn, S, et al.. Inequities in diabetic ketoacidosis among patients with type 1 diabetes and COVID-19: data from 52 US clinical centers. J Clin Endocrinol Metab 2021;106:1755–62. https://doi.org/10.1210/clinem/dgaa920.Search in Google Scholar PubMed PubMed Central

8. Elgenidy, A, Awad, AK, Saad, K, Atef, M, El-Leithy, HH, Obiedallah, AA, et al.. Incidence of diabetic ketoacidosis during COVID-19 pandemic: a meta-analysis of 124,597 children with diabetes. Pediatr Res 2022;93:1149–60. https://doi.org/10.1038/s41390-022-02241-2.Search in Google Scholar PubMed PubMed Central

9. Bergenstal, RM, Gal, RL, Connor, CG, Gubitosi-Klug, R, Kruger, D, Olson, BA, et al.. Racial differences in the relationship of glucose concentrations and hemoglobin a1c levels. Ann Intern Med 2017;167:95–102. https://doi.org/10.7326/m16-2596.Search in Google Scholar PubMed

10. Tai, DBG, Shah, A, Doubeni, CA, Sia, IG, Wieland, ML. The disproportionate impact of COVID-19 on racial and ethnic minorities in the United States. Clin Infect Dis 2020;72. https://doi.org/10.1093/cid/ciaa959.Search in Google Scholar PubMed PubMed Central

11. Bacha, F, Cheng, P, Gal, RL, Beaulieu, LC, Kollman, C, Adolph, A, et al.. Racial and ethnic disparities in comorbidities in youth with type 2 diabetes in the pediatric diabetes consortium (PDC). Diabetes Care 2021;44:2245–51. https://doi.org/10.2337/dc21-0143.Search in Google Scholar PubMed

12. Chalew, S, Kamps, J, Jurgen, B, Gomez, R, Hempe, J. The relationship of glycemic control, insulin dose, and race with hypoglycemia in youth with type 1 diabetes. J Diabet Complicat 2020;34:107519. https://doi.org/10.1016/j.jdiacomp.2019.107519.Search in Google Scholar PubMed PubMed Central

13. Chen, PJ, Pusica, Y, Sohaei, D, Prassas, I, Diamandis, EP. An overview of mental health during the COVID-19 pandemic. Diagnosis 2021;0.10.20944/preprints202103.0217.v1Search in Google Scholar

Received: 2024-10-30
Accepted: 2025-01-06
Published Online: 2025-02-06
Published in Print: 2025-04-28

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Original Articles
  3. Diabetes distress, depression, and future glycemic control among adolescents with type 1 diabetes
  4. Is oxytocin related to psychiatric symptoms in adolescents with obesity?
  5. Associations between body mass index and sleep duration in Brazilian children and adolescents: the moderating role of screen time
  6. The transfer of care experience in young adults with type 1 diabetes
  7. Assessing the efficacy of a hybrid closed loop system in a racial-ethnic minority cohort of children and adolescents with type 1 diabetes
  8. Do children with type 1 diabetes mellitus remain protected against hepatitis B?
  9. Influence of excess weight on metabolic risk factors in Argentinian preschool children
  10. Causal associations between childhood obesity and delayed puberty or height: a bidirectional two-sample Mendelian randomization study
  11. Differentiating true precocious puberty and puberty variants in consecutive 275 girls: a single center experience
  12. Development of bone mineral density and content in children with cerebral palsy: a retrospective, longitudinal study
  13. Insights in non-CAH pediatric primary adrenal insufficiency: a single-center experience from India
  14. Effect of empagliflozin treatment on laboratory and clinical findings of patients with glycogen storage disease type Ib: first study from Türkiye
  15. Clinical and laboratory characteristics of propionic acidemia in a Turkish cohort
  16. Short Communication
  17. The impact of the COVID-19 pandemic on DKA severity in Black and White pediatric patients
  18. Case Reports
  19. Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia
  20. DNA ligase IV deficiency identified in a patient with hypergonadotropic hypogonadism: a case report
  21. Moebius syndrome and hypopituitarism: a case of multiple pituitary hormone deficiency and revision of the literature
Downloaded on 10.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2024-0526/html
Scroll to top button